COVID-19 randomized controlled trials in medRxiv and PubMed

• This study investigated the difference between COVID-19 RCT in medRxiv and in PubMed. • SPIN in the conclusion was more frequently seen in reports in medRxiv than PubMed. • Readers should pay attention to the overstatements in preprints of COVID-19 RCT.

Detalles Bibliográficos
Autores principales: Kataoka, Yuki, Oide, Shiho, Ariie, Takashi, Tsujimoto, Yasushi, Furukawa, Toshi A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Federation of Internal Medicine. Published by Elsevier B.V. 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508503/
https://www.ncbi.nlm.nih.gov/pubmed/32981802
http://dx.doi.org/10.1016/j.ejim.2020.09.019
_version_ 1783585433889800192
author Kataoka, Yuki
Oide, Shiho
Ariie, Takashi
Tsujimoto, Yasushi
Furukawa, Toshi A.
author_facet Kataoka, Yuki
Oide, Shiho
Ariie, Takashi
Tsujimoto, Yasushi
Furukawa, Toshi A.
author_sort Kataoka, Yuki
collection PubMed
description • This study investigated the difference between COVID-19 RCT in medRxiv and in PubMed. • SPIN in the conclusion was more frequently seen in reports in medRxiv than PubMed. • Readers should pay attention to the overstatements in preprints of COVID-19 RCT.
format Online
Article
Text
id pubmed-7508503
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher European Federation of Internal Medicine. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-75085032020-09-23 COVID-19 randomized controlled trials in medRxiv and PubMed Kataoka, Yuki Oide, Shiho Ariie, Takashi Tsujimoto, Yasushi Furukawa, Toshi A. Eur J Intern Med Letter to the Editor • This study investigated the difference between COVID-19 RCT in medRxiv and in PubMed. • SPIN in the conclusion was more frequently seen in reports in medRxiv than PubMed. • Readers should pay attention to the overstatements in preprints of COVID-19 RCT. European Federation of Internal Medicine. Published by Elsevier B.V. 2020-11 2020-09-22 /pmc/articles/PMC7508503/ /pubmed/32981802 http://dx.doi.org/10.1016/j.ejim.2020.09.019 Text en © 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter to the Editor
Kataoka, Yuki
Oide, Shiho
Ariie, Takashi
Tsujimoto, Yasushi
Furukawa, Toshi A.
COVID-19 randomized controlled trials in medRxiv and PubMed
title COVID-19 randomized controlled trials in medRxiv and PubMed
title_full COVID-19 randomized controlled trials in medRxiv and PubMed
title_fullStr COVID-19 randomized controlled trials in medRxiv and PubMed
title_full_unstemmed COVID-19 randomized controlled trials in medRxiv and PubMed
title_short COVID-19 randomized controlled trials in medRxiv and PubMed
title_sort covid-19 randomized controlled trials in medrxiv and pubmed
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508503/
https://www.ncbi.nlm.nih.gov/pubmed/32981802
http://dx.doi.org/10.1016/j.ejim.2020.09.019
work_keys_str_mv AT kataokayuki covid19randomizedcontrolledtrialsinmedrxivandpubmed
AT oideshiho covid19randomizedcontrolledtrialsinmedrxivandpubmed
AT ariietakashi covid19randomizedcontrolledtrialsinmedrxivandpubmed
AT tsujimotoyasushi covid19randomizedcontrolledtrialsinmedrxivandpubmed
AT furukawatoshia covid19randomizedcontrolledtrialsinmedrxivandpubmed

Ejemplares similares